Insights from 4 Analyst Ratings on Schrodinger
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Source: Benzinga
Analyst Ratings Overview: Schrodinger (SDGR) received mixed ratings from four analysts, with two being somewhat bullish and two indifferent over the last quarter, reflecting a shift in sentiment compared to previous months.
Price Target Insights: Analysts have set an average 12-month price target of $23.5 for Schrodinger, down from $31.67, with estimates ranging from a low of $19.00 to a high of $30.00.
Financial Performance Metrics: Schrodinger's revenue growth rate is approximately 15.69%, but it struggles with profitability, showing a net margin of -78.84% and ROE of -12.05%, indicating challenges in cost management and equity utilization.
Debt Management Position: The company maintains a favorable debt-to-equity ratio of 0.33, suggesting a lower reliance on debt financing compared to industry averages, which may be viewed positively by investors.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like SDGR with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on SDGR
Wall Street analysts forecast SDGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SDGR is 21.83 USD with a low forecast of 18.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 14.570
Low
18.00
Averages
21.83
High
25.00
Current: 14.570
Low
18.00
Averages
21.83
High
25.00
About SDGR
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Surge: The global AI medical imaging market is projected to reach $2.57 trillion by 2026, driving the AI drug discovery sector to $1.81 billion, indicating a robust shift towards AI-native diagnostic precision in healthcare.
- Strong Investment Demand: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization and market expansion, marking a pivotal transition from development to revenue generation.
- Economic Value Proposition: VentriPoint is collaborating with Summit Sciences to develop ROI models that demonstrate measurable savings for hospitals through enhanced diagnostic accuracy and resource optimization, thereby strengthening its competitive position.
- Executive Appointment: The appointment of David Swetlow as CFO, with over 15 years of experience in medical technology, is expected to accelerate market adoption and revenue growth, facilitating the execution of the company's commercial strategy.
Continue Reading
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Potential: The global AI medical imaging market reached $2.57 trillion in 2026, driving the AI drug discovery sector to $1.81 billion, indicating a strong shift towards AI-native diagnostic precision in healthcare.
- Increased Funding: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization activities, manufacturing scale-up, and regulatory submissions, facilitating the company's transition from development to revenue generation.
- Economic Value Proof: VentriPoint partnered with Summit Sciences to develop ROI models that demonstrate measurable returns for hospitals through process improvements and resource optimization, emphasizing the economic rationale of their technology.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, leveraging his extensive management experience in medical technology to accelerate market adoption and drive revenue growth.
Continue Reading